SABSW
SAB Biotherapeutics, Inc.
—
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
None
$0.01
(0.00%)
Price History
52-Week Range
Sign in to add SABSW to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | 0.05 |
| Forward P/E | - |
| EPS (TTM) | $0.29 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -11.27% |
| Debt/Equity | 2.39 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | 0.53 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $0.03 |
| 52-Week Low | $0.01 |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | 3.3K |
Performance Analysis
BULLISHSABSW shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($0.01), which could present a value opportunity.
+
P/E of 0.1 suggests the stock may be undervalued.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 10, 2026 15:11 UTC
Back to Screener Export Report